Disitamab vedotin targets HER2, is internalized, and releases MMAE, which binds the beta-tubulin (vinca domain) to block microtubule polymerization, causing G2/M arrest and apoptosis. Killing depends on HER2-mediated delivery, not on beta-tubulin expression itself.